We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA SHOULD APPROVE GENERIC CONCERTA, LAW FIRM ARGUES
FDA SHOULD APPROVE GENERIC CONCERTA, LAW FIRM ARGUES
June 29, 2004
The FDA should use its currently accepted criteria for demonstrating bioequivalency to approve generic versions of McNeil Consumer & Specialty Pharmaceuticals’ attention deficit/hyperactivity disorder drug Concerta, argued a law firm in response to a McNeil citizen petition that has delayed generic entry.